MMMohammad Hadi Molseghi

Mohammad Hadi Molseghi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohammad Hadi Molseghi has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Midface defects caused by mucormycosis with a new classification: a retrospective study

    by Hamid Reza Fathi, Mohammad Mohammadi Arbati, Seyed Mousa Sadrhosseini, Mohammad Hadi Molseghi, Mahammad Davudov

    Background: The most complex and debated aspect of head and neck reconstructive surgery is the management of midface defects caused by malignant or non-malignant diseases. This study proposes a new classification system for patients with midface defects arising from non-malignant and non-traumatic diseases.Methods: In this study, 107 patients with midface defects resulting from mucormycosis were evaluated according to the anatomical locations of involvement and the differences between the affected areas.Results: Diabetes was identified as the most common underlying disease, while the paranasal sinuses were the most frequently involved sites in cases of mucormycosis. Fourteen patients developed mucormycosis without any associated risk factors, and one patient exhibited brain tissue involvement.Conclusion: To the best of our knowledge, this study is the first to present a comprehensive classification system for patients presenting with midface defects due to mucormycosis.

  • Open Access

    Effect of add‐on melatonin on seizure outcomes and quality of sleep in epilepsy with idiopathic generalized tonic‐clonic seizures alone in adult patients: Cross‐sectional, randomized, double‐blind, placebo‐controlled clinical trial

    by Mehdi Maghbooli, Somayeh Alyan NajafAbadi, Ghazal MalekMahmoudi, Mohammad Hadi Molseghi

    Background: Effective treatment of epilepsy is a major challenge in the field of neurology. Studies have suggested that melatonin can work in epilepsy with a good safety profile.Objectives: This study was performed to determine the effectiveness of melatonin in seizure outcomes, as well as the quality of sleep in patients with generalized epilepsy.Methods: In this cross‐over clinical trial study, 60 patients with epilepsy with idiopathic generalized tonic‐clonic seizures alone (EGTCS) and under valproic acid treatment received either melatonin or placebo with a washout period of 2 weeks intermittently. Outcome variables included a reduction in the severity and frequency of epilepsy besides improvement in electroencephalogram (EEG) abnormalities and sleep quality.Results: By adding melatonin, a decrease in the mean severity score of epilepsy (according to the Chalfont questionnaire) was 32.33 ± 9.24, while it was 5.58 ± 14.28 in treatment with placebo (p = .002). Evaluation of the number of attacks and EEG results did not disclose any therapeutic efficacy in treatment with melatonin versus placebo. The quality of sleep improved in 40% (first round) and 53.4% (second round) of subjects who received melatonin (p < .001).Conclusions: Considering that the addition of melatonin to routine anti‐seizure treatment was effective in reducing the severity of epilepsy and improving sleep quality, it seems that melatonin can be useful as an adjunct therapy for EGTCS in well‐defined circumstances.


  • Open Access

    COVID-19 Presenting as Acute Necrotizing Pancreatitis

    by Mohammad Mohammadi Arbati, Mohammad Hadi Molseghi

    The ongoing pandemic of the novel coronavirus disease 2019 (COVID-19) originated in Wuhan, China, in December 2019. Various manifestations of coronavirus (SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2]) have been reported since the pandemic began. Some articles have reported acute pancreatitis in several patients due to COVID-19 infection. In this case report, we introduce a patient in whom SARS-CoV-2 caused necrotizing pancreatitis. Acute abdomen is one of the manifestations of COVID-19. Various causes such as acute pancreatitis and necrotizing pancreatitis can be in the list of differential diagnoses.


  • Helicobacter Pylori Infection in Sjögren’s Syndrome: Co-incidence or Causality?

    by Massoud Saghafi, Nafiseh Abdolahi, Reza Orang, Mohammad Reza Hatef, Mohammad Hadi Molseghi

    Background and Aim: Lymphoid cell infiltration and destruction of exocrine glands, specifically lacrimal and salivary glands are characteristics of Sjogren’s syndrome (SS). An etiological role has been proposed for Helicobacter pylori (H.Pylori), interacting in the clinical course and complications of SS (including gastric cancer and lymphoma). The aim of this study was to identify the probable correlation between H. pylori infection and Sjogren’s syndrome (SS). Method: In this case-control study, ELISA method was used to determine serum level of IgA and IgM anti H. pylori antibody in 43 subjects with SS according to the international criteria and 95 healthy subjects as control. SPSS-17 was used to analysis data with t-test. P value <0.05 were considered significant. Results: Serum level of IgM (34.9% vs 10.5%, p-value= 0.001) and IgA (67.4% vs 46.3% p value= 0.021) anti H.Pylori antibody were significantly higher in SS patients compared to the control group. There was a positive correlation between age and H.Pylori infection (r=0.2, P-value=0.05). Conclusions: Patients with SS had a higher prevalence of H. pylori infection compared to the normal population. Eradication of H.Pylori is recommended particularly in older patients with SS.


  • Open Access

    Hematologic Changes in Patients with Graves’ disease in Gorgan During 2014-2015

    by Maryam Zahedi, Farzam Mirkamali, Sharabeh Hezarkhani, Armineh Motiee, Arash Rezaei Shahmirzadi, Mohammad Hadi Molseghi, Reza Alipoor

    Background: The most common cause of hyperthyroidism in areas without iodine deficiency is Graves’ disease. There are reports of some hematological alterations in hyperthyroidism. This study was designed to measure the hematologic profile in the patients with Graves’ disease before and after the treatment.Methods: In this cross-sectional study, 100 patients were selected with convenience sampling that diagnosed as autoimmune Graves’ disease in our academic endocrinology clinic during 2014-2015. Inclusion criteria included autoimmune hyperthyroidism in patients who were referred to this center during the study period. Patients who refused to take part in the research, had recent infections disease, malignancies, surgical procedures, severe trauma, received immunosuppressive drugs or corticosteroids, high erythrocyte sedimentation rate (ESR) values during the last six months, and not responded to treatment with methimazole were excluded from the study. The simple sampling technique was used to select the patients. A complete blood count (CBC) was taken before and after treatment. The P-value less than 0.05 was considered as the statistical significance level. All data were analyzed using the Statistical Package for the Social Sciences 16.0 (SPSS Inc., Chicago, IL, USA) software.Results: One hundred patients with a mean age of 38 ± 9.8 years were included. There were no significant changes in the white blood cells (WBC) count, red blood cells (RBC) count, and platelets. Mild anemia (Hb=12.16±1.23) present before treating the hyperthyroidism that was significantly improved after treatment (P= 0.000). Conclusions: Our results showed that the only significant hematologic change in patients with Graves’ disease was mild anemia that improves after treating the underlying thyroid disorder.

  • Ventricular endomyocardial fibrosis in a pregnant female with Behçet’s disease

    by Zahra Mirfeizi, Bahram Memar, Hoorak PourZand, Mohammad Hadi Molseghi, Arash Rezaei Shahmirzadi, Nafiseh Abdolahi

    A 32-year-old pregnant woman, diagnosed with Behçet’s disease 6 months earlier, presented with recent mild hemoptysis and exertional dyspnea. Transthoracic echocardiography showed an enlarged dysfunctional right ventricle. A large hypoechoic triangular-shaped mass was seen attached to the inner right ventricular wall, filling the cavity. No change in the size of the mass was noted after anticoagulant administration, and right heart failure progressed. Surgery was performed to remove the mass and repair the tricuspid valve. This was a very rare presentation of Behçet’s disease in pregnancy, which resulted in delivery of a completely healthy baby despite corticosteroid pulse therapy and cyclophosphamide.